【产品介绍】：

生物活性：rac cis-Moxifloxacin-d4 (hydrochloride) is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].
IC50 & Target：Quinolone
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
rac cis-Moxifloxacin-d4 hydrochloride 相关抗体:
MRP2 Antibody
Elongation factor 2 Antibody (YA962)
Elongation factor 2 Antibody (YA964)
PU.1/SPI1 Antibody (YA1116)
Sulfadimidine Antibody (YA906)
Elongation factor 2 Antibody (YA963)
Anthrax Protective gen Antibody (YA1060)
Elongation factor 1 gamma Antibody (YA2004)
Pulmonary Surfactant Associated Protein D Antibody (YA2107)
Cathelicidin Antibody (YA2380)
Elongation Factor Ts Antibody (YA2524)
Elongation Factor 1A2 Antibody (YA2879)
BPI Antibody (YA3068)
MetRS Antibody (YA3196)
分子量：441.92
Formula：C21H21D4ClFN3O4
CAS 号：1217802-65-7
非标记 CAS：186826-86-8
性状：固体
颜色：White to light yellow
中文名称：盐酸莫西沙星 d4 (盐酸盐)
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Store at room temperature, keep dry and cool
In solvent：-80°C：2 years
-20°C：1 year
纯度 & 产品资料
纯度： 99.78%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Culley CM, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm. 2001 Mar 1;58(5):379-88.
 [Content Brief]
[3]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39.
 [Content Brief]
[4]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702.
 [Content Brief]
[5]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102.
 [Content Brief]